Recessive dystrophic epidermolysis bullosa
MONDO:0009179Severe generalized recessive dystrophic epidermolysis bullosa (RDEB-sev gen) is the most severe subtype of dystrophic epidermolysis bullosa (DEB), formerly known as the Hallopeau-Siemens type, and is characterized by generalized cutaneous and mucosal blistering and scarring associated with severe deformities and major extracutaneous involvement.
Also known as: EBD inversa, RDEB generalisata gravis, RDEB, Hallopeau-Siemens type, RDEB-sev gen, autosomal recessive dystrophic epidermolysis bullosa generalisata gravis, autosomal recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens type, epidermolysis bullosa dystrophica, AR, epidermolysis bullosa dystrophica, autosomal recessive, modifier of
21 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Gene therapy skin graft aims to heal wounds in 'Butterfly Children'
Disease control Not yet recruitingThis trial evaluates a gene therapy skin graft called prademagene zamikeracel (pz-cel) for treating wounds in people with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic condition that causes fragile skin and chronic wounds. The study includes three parts: one…
Phase: PHASE4 • Sponsor: Abeona Therapeutics, Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for blistering skin diseases: drug targets antibodies to heal wounds
Disease control Not yet recruitingThis early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA)…
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Anti-Inflammatory drug may ease swallowing in rare skin disease
Symptom relief Not yet recruitingThis study investigates whether budesonide, an anti-inflammatory medication, can improve swallowing difficulties in people with dystrophic epidermolysis bullosa, a rare genetic condition that causes fragile skin and scarring. The researchers will review medical records of 15 pati…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New cream aims to soothe butterfly skin in Late-Stage trial
Symptom relief Not yet recruitingThis Phase 3 study tests the safety of SD-101 cream (6% allantoin) in 80 people with epidermolysis bullosa, a condition that causes fragile, blistering skin. Participants must have completed a prior study (SD-007). The main goal is to track any side effects over time.
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC